HomepageFTRE • NASDAQ
add
Covance
$Â 6,15
Na sluitingstijd:(1,63%)+0,100
$Â 6,25
Gesloten: 9 mei, 20:00:00 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$Â 5,95
Dag-range
$Â 5,84 - $Â 6,33
Jaar-range
$Â 4,77 - $Â 35,92
Beurswaarde
556,82Â mln. USD
Gem. volume
2,59Â mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | dec 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 697,00Â mln. | -1,79% |
Bedrijfskosten | 168,90Â mln. | 13,43% |
Netto inkomsten | -61,20Â mln. | -12,29% |
Netto winstmarge | -8,78 | -14,32% |
Winst per aandeel | 0,18 | -5,26% |
EBITDA | -7,20Â mln. | -241,18% |
Effectief belastingtarief | 1,34% | — |
Balans
Totale activa
Totale passiva
(USD) | dec 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 118,50Â mln. | 9,12% |
Totale activa | 3,58Â mld. | -17,39% |
Totale passiva | 2,22Â mld. | -15,34% |
Totaal aandelenvermogen | 1,36 mld. | — |
Uitstaande aandelen | 90,20 mln. | — |
Koers-boekwaardeverhouding | 0,39 | — |
Rendement op activa | -1,93% | — |
Rendement op kapitaal | -2,65% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | dec 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -61,20Â mln. | -12,29% |
Operationele kasstroom | 17,10Â mln. | -7,07% |
Kasstroom uit beleggingen | 3,50Â mln. | 138,89% |
Kasstroom uit financiering | -1,10Â mln. | 85,71% |
Nettomutatie in liquide middelen | 13,20Â mln. | 175,00% |
Vrije kasstroom | 90,21Â mln. | 1.006,90% |
Over
Fortrea Holdings Inc. is a contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates. Wikipedia
Opgericht
apr 1996
Website
Werknemers
15.810